Daily Ards Research Analysis
Key advances today include a meta-analysis suggesting sivelestat may reduce mortality in septic ARDS, a multicenter study defining a fulminant sCAP phenotype with early deaths largely from ARDS and multiorgan failure and showing an association between early corticosteroids and reduced 7-day mortality, and a prospective diagnostic study indicating fetal main pulmonary artery Doppler indices can predict neonatal RDS severity.
Summary
Key advances today include a meta-analysis suggesting sivelestat may reduce mortality in septic ARDS, a multicenter study defining a fulminant sCAP phenotype with early deaths largely from ARDS and multiorgan failure and showing an association between early corticosteroids and reduced 7-day mortality, and a prospective diagnostic study indicating fetal main pulmonary artery Doppler indices can predict neonatal RDS severity.
Research Themes
- Therapeutics for septic ARDS (neutrophil elastase inhibition)
- Time-critical phenotyping and early management in severe pneumonia
- Antenatal noninvasive prediction of neonatal respiratory outcomes
Selected Articles
1. Sivelestat for septic patients with acute respiratory distress syndrome: a systematic review and meta-analysis of a deadly duo.
Across 17 studies (n=5,062), sivelestat use in septic ARDS was associated with lower mortality (OR 0.63, 95% CI 0.48–0.84). The review incorporated GRADE, subgroup, sensitivity, and regression analyses and was prospectively registered.
Impact: Provides the most comprehensive synthesis to date suggesting a survival benefit of neutrophil elastase inhibition in septic ARDS, guiding trial design and cautious clinical consideration.
Clinical Implications: Consider sivelestat as a candidate adjunct in septic ARDS where available, while awaiting confirmatory high-quality RCTs; prioritize patients within contexts similar to included studies.
Key Findings
- Across 17 studies (n=5,062), sivelestat was associated with reduced mortality versus controls (OR 0.63, 95% CI 0.48–0.84).
- Quality assessment included GRADE; heterogeneity was explored via subgroup, sensitivity, and regression analyses.
- The review was prospectively registered (INPLASY202560111).
Methodological Strengths
- Prospective protocol registration and use of GRADE framework
- Comprehensive heterogeneity exploration (subgroup, sensitivity, regression)
Limitations
- Potential heterogeneity from mixed study designs and settings
- Unclear proportion of randomized evidence; risk of publication bias
Future Directions: Conduct large, multicenter, CONSORT-compliant RCTs to confirm mortality benefit, define optimal timing/dosing, and identify responsive subgroups in septic ARDS.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is one of the most common organ dysfunctions in sepsis. The potential benefits of sivelestat, a selective inhibitor of neutrophil elastase, for patients with septic ARDS remain unclear. The current systematic review and meta-analysis aimed to evaluate the effectiveness of sivelestat in reducing mortality and improving other important outcomes in this patient population. METHODS: We searched PubMed, EMBASE, and Cochrane Library databases until May 30, 2025, for studies comparing sivelestat in septic patients with ARDS against controls. The primary outcome was mortality. We assessed study quality and conducted subgroup analyses, sensitivity analyses, regression analyses, and GRADE evaluations to explore potential heterogeneity. RESULTS: A total of 17 studies involving 5,062 patients met the inclusion criteria. Overall, sivelestat significantly reduced the risk of mortality compared to controls (odds ratio [OR] = 0.63; 95% confidence interval [CI], 0.48-0.84; CONCLUSION: Sivelestat significantly increased PaO SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/wp-content/uploads/2025/06/INPLASY-Protocol-7969.pdf, identifier INPLASY202560111.
2. Predicting neonatal RDS with fetal pulmonary artery doppler: a diagnostic performance and ROC curve analysis.
Fetal main pulmonary artery Doppler indices (At/Et, PI, RI) predicted neonatal RDS, with effective cutoffs (At/Et <0.24, RI >0.8, PI >2.16). Indices tracked gestational maturation and independently predicted RDS and its severity in preterm neonates.
Impact: Offers a noninvasive, antenatal risk stratification method that could guide perinatal planning and early respiratory support strategies.
Clinical Implications: Integrate fetal MPA Doppler indices into late-gestation surveillance for at-risk pregnancies to anticipate neonatal RDS, prepare surfactant/CPAP resources, and optimize delivery timing.
Key Findings
- At/Et increased while PI and RI decreased with advancing gestation in normally developing fetuses.
- Neonates who developed RDS had low At/Et and elevated PI and RI; cutoffs At/Et <0.24, RI >0.8, PI >2.16 predicted RDS.
- Altered Doppler indices independently predicted RDS and correlated with severity in preterm neonates.
Methodological Strengths
- Prospective diagnostic accuracy design with predefined Doppler indices averaged over multiple cardiac cycles
- Assessment of maturation trends and postnatal outcomes with ROC-informed cutoffs
Limitations
- Sample size not reported in the abstract; external validity uncertain
- Operator dependence and potential single-center bias not addressed in abstract
Future Directions: Validate cutoffs in larger, multicenter cohorts; standardize acquisition protocols; evaluate integration with other antenatal biomarkers for composite risk models.
STUDY DESIGN: Prospective observational diagnostic accuracy study. METHODS: This study evaluated Doppler parameters of the fetal main pulmonary artery (MPA) as potential non-invasive predictors of RDS and to assess their relationship with gestational age and postnatal respiratory outcomes. Pulsed-wave Doppler of the fetal MPA was performed and Doppler indices-pulsatility index (PI), resistance index (RI), peak systolic velocity (PSV), and acceleration time/ejection time ratio (At/Et)-were recorded over three cardiac cycles and averaged. Values were compared after delivery between neonates with and without RDS. RESULTS: In normally developing fetuses, PI and RI decreased while At/Et increased with advancing gestational age. In contrast, fetuses who developed RDS showed persistently low At/Et and elevated PI and RI values. Cutoff values of At/Et < 0.24, RI > 0.8, and PI > 2.16 were effective in predicting RDS. The severity of RDS was associated with greater deviations from these values. Altered Doppler indices were found to be independent predictors of RDS in preterm neonates. CONCLUSION: Fetal MPA Doppler parameters serve as reliable, non-invasive predictors of RDS and the severity of RDS in preterm neonates.
3. Existence and relevance of fulminant severe community-acquired pneumonia.
In 1,517 sCAP admissions, fulminant cases (death ≤7 days) comprised 5.9%, with early deaths largely due to ARDS, sepsis, and multiorgan failure. Early corticosteroid administration was associated with markedly reduced 7-day mortality (OR 0.22, 95% CI 0.12–0.38).
Impact: Defines a time-critical sCAP phenotype with quantifiable incidence and actionable early risk factors, informing emergency triage and early therapeutic strategies.
Clinical Implications: Screen sCAP patients at admission for fulminant risk (age, obesity, diabetes, CVD, creatinine) and consider early corticosteroids while awaiting RCT confirmation, with vigilant ARDS prevention/management protocols.
Key Findings
- Fulminant sCAP (death within 7 days) occurred in 5.9% of 1,517 hospitalized sCAP patients.
- Early deaths were primarily due to ARDS (93%), sepsis (70%), and multiorgan failure (73%).
- Early corticosteroid administration was associated with reduced 7-day mortality (OR 0.22, 95% CI 0.12–0.38); older age, obesity, diabetes, CVD, and elevated creatinine increased risk.
Methodological Strengths
- Multicenter retrospective cohort with large sample (n=1,517) and predefined fulminant definition
- Multivariable analyses identifying risk and protective factors
Limitations
- Retrospective design with potential residual confounding and indication bias
- Causality for corticosteroid effect cannot be inferred; external validation needed
Future Directions: Prospective validation and randomized trials to test early corticosteroid strategies in fulminant-risk sCAP; development of rapid bedside risk scores.
BACKGROUND: Severe community-acquired pneumonia (sCAP) is a major contributor to global hospital mortality, with some patients rapidly progressing to death within a few days due to acute respiratory distress syndrome (ARDS), septic shock, or multiorgan failure (MOFS). Despite the significant health burden, these cases remain poorly defined, often overlooked in clinical practice, and insufficiently addressed in existing guidelines. METHODS: In this multicenter retrospective study, we analyzed 1,517 hospitalized patients with sCAP for assessing the incidence of fulminant pneumonia -defined as sCAP leading to death within 7 days from hospital admission- and to identify factors associated with either an increased or reduced risk of unfavorable outcome. RESULTS: Our findings revealed a 5.9% incidence of fulminant pneumonia, with early death primarily due to ARDS (93%), sepsis (70%), and MOFS (73%). Older age, obesity, diabetes, cardiovascular disease, and elevated serum creatinine were associated with increased risk, while early corticosteroid administration was associated with a significant mortality reduction within seven days, both in the univariate and multivariate analyses (OR 0.22, CI 95% 0.12–0.38, CONCLUSION: These findings highlight the importance of recognizing sCAP as a time-dependent condition, requiring early identification and treatment of cases at risk for developing fulminant pneumonia at hospital admission. Larger studies and randomized controlled trials are necessary to validate these findings and optimize treatment strategies. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT06516601.